Loading
Everything in development, the open problems and what is being done about them, the roadmaps, and what changed on this record.
What is in development for Chordoma, drawn from the whole corpus: 5 items. Drugs are grouped by the most advanced trial phase they have reached anywhere; approved treatments sit under standard of care. Technologies are the methods being tested for this cancer, trials are the studies recorded here, and ideas are proposals not yet in a trial.
No approved systemic therapy: trials of brachyury-directed vaccines, degraders and EGFR inhibitors are the response.
Recurrent skull-base disease after full-dose radiotherapy: re-irradiation with particles and salvage surgery are being studied.
Also on OnCo: Treatment journeys · Survivorship planner.
Paediatric poorly differentiated chordoma: tazemetostat and SWI/SNF-directed trials.
Access to particle therapy, which remains concentrated in a few countries.
Nothing recorded yet.
Nothing recorded yet.
Also on OnCo: Financial help · Coverage by country · HTA decisions.
Dated changes read from the records linked to this cancer: approvals, regulatory steps, reported trials, guideline versions and milestones. Newest first; no date is inferred.
On EdgeAll 10 changes by month →When this page itself was last checked or edited.
Phase 2 of GI-6301 yeast-brachyury vaccine with radiation (NCT02383498).
WHO classification of soft tissue and bone tumours, fifth edition.
Regorafenib improved eight-week progression-free survival over placebo in relapsed osteosarcoma, with signals in the Ewing sarcoma and chondrosarcoma cohorts.
En bloc resection with negative margins by a spine or skull-base team, followed by high-dose proton or carbon-ion radiotherapy; intralesional surgery is associated with early recurrence. (NCCN Category 2A)
First international recommendations on surgery, radiotherapy and systemic therapy (Lancet Oncol).